Johnson & Johnson (NYSE:JNJ) Shares Sold by Nilsine Partners LLC

Nilsine Partners LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,067 shares of the company’s stock after selling 103 shares during the period. Nilsine Partners LLC’s holdings in Johnson & Johnson were worth $3,016,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Centennial Wealth Advisory LLC increased its position in Johnson & Johnson by 6.2% in the 1st quarter. Centennial Wealth Advisory LLC now owns 1,635 shares of the company’s stock valued at $259,000 after acquiring an additional 95 shares during the period. America First Investment Advisors LLC increased its position in Johnson & Johnson by 3.4% in the 1st quarter. America First Investment Advisors LLC now owns 111,825 shares of the company’s stock valued at $17,690,000 after acquiring an additional 3,692 shares during the period. HF Advisory Group LLC increased its position in Johnson & Johnson by 5.5% in the 1st quarter. HF Advisory Group LLC now owns 4,807 shares of the company’s stock valued at $761,000 after acquiring an additional 252 shares during the period. PFG Investments LLC boosted its holdings in Johnson & Johnson by 431.2% in the 1st quarter. PFG Investments LLC now owns 109,278 shares of the company’s stock valued at $17,287,000 after purchasing an additional 88,707 shares in the last quarter. Finally, Oakworth Capital Inc. boosted its holdings in Johnson & Johnson by 10.8% in the 1st quarter. Oakworth Capital Inc. now owns 21,780 shares of the company’s stock valued at $3,445,000 after purchasing an additional 2,130 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Bank of America lowered their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada decreased their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Finally, Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $2.21 during trading on Tuesday, hitting $144.61. 8,814,891 shares of the company were exchanged, compared to its average volume of 7,383,957. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The stock has a market capitalization of $348.48 billion, a price-to-earnings ratio of 9.02, a P/E/G ratio of 2.41 and a beta of 0.53. The firm has a 50 day moving average price of $154.80 and a 200 day moving average price of $155.14.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the previous year, the firm posted $2.68 EPS. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.43%. Johnson & Johnson’s payout ratio is 29.68%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.